Staphylococcus Lugdunensis Prosthetic Joint Infection

Completed

• Conditions: Staphylococcal Infections; Prosthetic Joint Infection
• Interventions: Other: Prothestic joint infection due to Staphylococcus lugdunensis

• Registration Number: NCT04409392
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

Staphylococcus lugdunensis is a coagulase-negative staphylococcus belonging to the human commensal cutaneous flora, and has been little studied in the field of prosthetic joint infections. However, it shares many virulence traits with Staphylococcus aureus, including many adhesins and its ability to form biofilm, and the few series of cases reports a significant failure rate.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-05-27
• Study First Submitted QC: 2020-05-27
• Study First Posted: 2020-06-01
• Status Verified: 2020-11
• Study Start: 2021-02-01
• Primary Completion: 2021-04-01
• Study Completion: 2021-04-01
• Last Update Submitted: 2021-06-15
• Last Update Posted: 2021-06-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 84

Inclusion Criteria

• infection of joint prosthesis (whatever its type) with Staphylococcus lugdunensis defined by the positivity of at least 2 gold-standard samples (joint puncture, intraoperative samples) with S. lugdunensis; OR
• a single positive gold-standard sample or positive blood cultures AND formal clinical, radiological, biological and / or pathological arguments in favor of an infection of joint prosthesis AND absence of other pathogenic agent

Read More

Exclusion Criteria

• none

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Prothestic joint infection due to Staphylococcus lugdunensis	Prothestic joint infection due to Staphylococcus lugdunensis	Patients having had a prosthetic joint infection with Staphylococcus lugdunensis

Primary Outcome Measures

Name	Time	Method
Description of patients with PJI infection due to Staphylococcus lugdunensis : surgical treatment	Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption	description of surgery performed : DAIR, one-step exchange, two-step exchange
Rate of PJI infection with Staphylococcus lugdunensis	between 2010 and 2020	proportion of patients having PJI infection with Staphylococcus lugdunensis, alone or with other bacteria
Description of PJI infection with Staphylococcus lugdunensis : type	Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption	type of PJI : knee or hip prosthesis
Description of patients with PJI infection due to Staphylococcus lugdunensis : follow up	Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption	duration of the follow up of patients
Description of patients with PJI infection due to Staphylococcus lugdunensis : medical treatment	Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption	description and duration of antibiotics
Description of patients with PJI infection due to Staphylococcus lugdunensis	Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption	type of patients: age, CMI
Description of PJI infection with Staphylococcus lugdunensis : evolution	Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption	evolution of PJI :evolution between prosthesis placement and the onset of symptoms, gateway to infection
rate of treatment failure	Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption	Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin

Trial Locations

Locations (1)

Hospices Civils de Lyon; 🇫🇷 Lyon, France